A5058402704- Inflammatory Bowel Disease
- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Pharmaceutical studies and practices
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
- Helicobacter pylori-related gastroenterology studies
- Autoimmune and Inflammatory Disorders Research
- SARS-CoV-2 and COVID-19 Research
- Health Systems, Economic Evaluations, Quality of Life
- Celiac Disease Research and Management
- Peripheral Neuropathies and Disorders
- Renal Transplantation Outcomes and Treatments
- Clostridium difficile and Clostridium perfringens research
- Mycobacterium research and diagnosis
- COVID-19 Clinical Research Studies
- Diverticular Disease and Complications
- Psoriasis: Treatment and Pathogenesis
- Pregnancy and Medication Impact
- Diversity and Career in Medicine
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastrointestinal motility and disorders
- Autoimmune and Inflammatory Disorders
- Gastrointestinal disorders and treatments
Hospital Universitario Reina Sofía
2018-2025
Instituto Maimónides de Investigación Biomédica de Córdoba
2019-2025
Western General Hospital
2022-2025
University of Córdoba
2022-2025
Cordoba University
2024-2025
NHS Lothian
2023-2025
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2019-2025
Centre for Biomedical Network Research on Rare Diseases
2025
Medical Research Network
2024
Centro de Investigación Biomédica en Red
2024
BackgroundThe effects that therapies for inflammatory bowel disease (IBD) have on immune responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we sought determine whether COVID-19 vaccine-induced antibody were altered in patients with IBD commonly used immunosuppressive drugs.MethodsIn this multicentre, prospective, case-control study (VIP), recruited adults treated one of six different treatment regimens (thiopurines, infliximab, a thiopurine plus ustekinumab, vedolizumab,...
BackgroundCOVID-19 vaccine-induced antibody responses are reduced in patients with inflammatory bowel disease (IBD) taking anti-TNF or tofacitinib after two vaccine doses. We sought to assess whether immunosuppressive treatments were associated and T-cell IBD a third dose.MethodsVIP was multicentre, prospective, case-control study done nine centres the UK. recruited immunosuppressed non-immunosuppressed healthy individuals. All participants aged 18 years older. The control group had no...
Background Upadacitinib is a Janus kinase inhibitor, which has recently been approved for treating Crohn’s disease. There are limited real-world studies on the outcomes of upadacitinib in Objective Our aim was to evaluate disease cohort. Methods We conducted retrospective, multicentre, cohort study over 2-year period across National Health Service (NHS) Lothian and Royal Devon University Healthcare NHS Foundation Trust. The primary outcome treatment persistence at week 24. Secondary...
Abstract Background Switching from originator infliximab (IFX) to biosimilar IFX is effective and safe. However, data on multiple switching are scarce. The Edinburgh inflammatory bowel disease (IBD) unit has undertaken three switch programmes: (1) Remicade CT‐P13 (2016), (2) SB2 (2020), (3) (2021). Objective primary endpoint of this study was assess persistence following SB2. Secondary endpoints included stratified by the number switches (single, double triple), effectiveness safety. Methods...
Filgotinib is a small molecule with preferential inhibition of Janus kinase type 1, approved for the treatment ulcerative colitis in Scotland May 2022. We present first real world experience on its use clinical practice.
Summary Background and Aims Data on the outcomes after switching from adalimumab (ADA) originator to ADA biosimilar are limited. The aim was compare treatment persistence, clinical efficacy, safety in inflammatory bowel disease patients who maintained vs. those switched biosimilar. Methods Patients receiving were remission at standard dose of included. formed non‐switch cohort (NSC), different biosimilars constituted switch (SC). Clinical defined as a Harvey–Bradshaw index ≤4 Crohn's partial...
Abstract Background Patients with IBD suffer a high prevalence of psychological disorders. The impact psychosocial factors on the risk disease flare is unknown. We aimed to assess associations between and flare. Methods PREdiCCt study largest prospective causes 2629 patients in clinical remission were recruited from 47 UK sites followed up for 24 months. At entry, completed questionnaires evaluating anxiety (HADS-A), depression (HADS-D), sleep quality (PSQI), physical activity (GPAQ)...
Abstract Background Numerous studies have implicated hormonal contraceptive therapy (HCT) as a potential trigger for IBD onset. However, data regarding disease flares in users are limited ulcerative colitis (UC). This study aims to explore this association. Methods Female patients who were diagnosed with UC after 1st January 2014, and born between 1966-2008 included. The Andersen-Gill extension of the Cox proportional hazards model was used account recurrent events within same subjects. Two...
Abstract Background Clostridioides difficile infection (CDI) represents the leading cause of nosocomial diarrhea in Western world. Patients with ulcerative colitis (UC) have a higher risk developing this infection, which has been associated an increased flare-ups, need for surgery, and mortality. The aim present study was to evaluate impact patients hospitalized UC flare-up. Methods Retrospective case-control including all flare-up at Reina Sofía Hospital Córdoba between January 2000 2023....
Abstract Background Despite major advances in our understanding of the molecular underpinning IBD, we remain challenged deciphering observed disease heterogeneity. Attempts to characterise longitudinal behaviour have either been restricted symptom-based profiling - as exemplified IBSEN cohorts or reliance on stochastic endpoints “progression” such hospitalisation, surgery and fibrosis. Here present a novel method examine IBD by modelling inflammatory patterns two large, well-characterised...
Abstract Background Upadacitinib (UPA) was approved in April 2023 for the treatment of moderate and severe active Crohn’s disease (CD) by European UK regulators (EMA / MHRA). Current real-world datasets are limited small size short follow-up. We aimed to evaluate long-term outcomes UPA a cohort. Methods performed retrospective cohort study, including all CD patients commenced on from October 2022 July 2024 Lothian, Scotland. Detailed patient phenotyping laboratory data were extracted...
The understanding and clinical management of inflammatory bowel disease (IBD) have evolved rapidly since ulcerative colitis Crohn’s were first described in 1859 1913, respectively. Over this time, certain landmark studies stand out for their impact the field IBD, leaving a lasting imprint on our pathology, treatments strategies optimal care, informing us best way to use new therapies, as well how deliver surgical care improve outcomes ultimately quality life. Our multinational group...
Biliary brushing cytology during endoscopic retrograde cholangiopancreatography (ERCP) is used to assess the nature of a biliary stricture. Its low sensitivity challenges exclusion malignancy through this technique. The aim was evaluate diagnostic yield brush in strictures and identify predictive factors associated with positive diagnosis malignancy. Observational retrospective study tertiary center. All adult patients undergoing ERPC from 2016 2022 were included. Logistic regression...
An estimated 2.5-3 million individuals (0.4%) in Europe are affected by inflammatory bowel disease (IBD). Whilst incidence rates for IBD stabilising across Europe, the prevalence is rising and subsequently resulting a significant cost to healthcare system of an 4.6-5.6 billion euros per year. Hospitalisation surgical resection generally on downward trend, which contrary novel medication. This signifies large part burden. Despite publicly funded systems most European countries, there still...
Background: Long-term vedolizumab (VDZ) outcomes in real-world cohorts have been largely limited to 1-year follow-up, with few bio-naïve patients or objective markers of inflammation assessed. Objectives: We aimed assess factors affecting VDZ persistence including clinical, biochemical and faecal biomarker remission at 1, 3 5 years. Design: performed a retrospective, observational, cohort study. Methods: All adult inflammatory bowel disease (IBD) who had received induction for ulcerative...
Abstract Background The evidence for the impact of increased advanced therapy prescribing on colectomy rates in ulcerative colitis (UC) are conflicting. Our aim was to describe trends therapies (biologics and small molecules) patients with UC Lothian, UK (elective emergency) between January 1st, 2004, December 31st, 2023. Methods Incidence prevalence data were obtained from validated Lothian IBD Registry. We identified who commenced an using multiple administrative databases, underwent NHS...
Abstract Background Ulcerative colitis (UC) is a chronic condition characterized by relapsing-remitting course, leading to cumulative systemic damage and disease progression. This progression may include extension of colitis, new extraintestinal manifestations (EIMs), dysplasia/colorectal cancer (CRC), the need for colectomy. study aimed compare based on time diagnosis, assess impact therapeutic options. Methods Retrospective at Reina Sofía University Hospital, analyzing all UC patients...